CME Activity: HER2-Mutated NSCLC Treatment Update

A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)

Conditions : Carcinoma, Non-Small-Cell Lung Sponsors : Janssen-Cilag Farmaceutica Ltda. Not yet recruiting

A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.

Conditions : Non-Small Cell Lung Cancer; Adjuvant Therapy Interventions : Drug: Third-generation EGFR-TKI Sponsors : First Affiliated Hospit

A Multicenter Randomized Open-Label Trial Evaluating MRD-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

Conditions : NSCLC (Advanced Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Carcinoma); NSCLC;

Lung cancer treatments in the era of personalized medicine

Using an individual patient's genetic code helps doctors select treatments most likely to be effective, and that includes for lung cancers,

<![CDATA[Practical Toxicity Monitoring and Multidisciplinary Management in HER2-Positive Metastatic Breast Cancer]]>

Miguel Gonzalez Velez: New Study on Real-World HER2-Mutant NSCLC Outcomes

Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center, Hackensack University Medical Center, shared JCO Precision Oncology